ArticleAdvanced materials (Deerfield Beach, Fla.)2026
Dendrimers Improve Apolipoprotein Nanoparticle mRNA Delivery to Immune Cells.
Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Targeted delivery of mRNA to immune cells forDrug delivery · 2026Review
- Programming the immunological properties of mRNA vaccines for cancer.Nature reviews. Immunology · 2026Review
- Unlocking the potential of mRNA nanomedicines for comprehensive fibrosis therapy.Molecular therapy. Nucleic acids · 2026Review
- Delivery of mRNA Therapeutics Beyond Infectious Diseases: Design Innovations and Applications in Oncology, Cardiovascular, and Rare Genetic Diseases.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Dendrimers Improve Apolipoprotein Nanoparticle mRNA Delivery to Immune Cells.Advanced materials (Deerfield Beach, Fla.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
Employing messenger RNA (mRNA) for protein production in the liver or for vaccine purposes is a promising therapeutic approach. However, unlocking mRNA's full therapeutic potential requires systemic delivery platform technology with controllable biodistribution features. Apolipoprotein nanoparticles (aNP) containing monovalent ionizable cationic lipids have been shown to functionally deliver mRNA to myeloid progenitor cells in the bone marrow after intravenous administration. Here, the development of polyvalent ionizable cationic dendrimers is reported for incorporation in aNPs to enable efficient mRNA complexation and functional delivery. A library of dendrimers is first rationally designed with diverse hydrophobic core units, a number of branching units, and functionalized terminal units. Upon incorporation, eleven distinct dendrimer-based aNP-mRNA formulations are screened and characterized in vitro for their properties. Based on the screening outcome, four formulations are selected and evaluated their ability to induce functional gene expression in vivo. The results indicate that the lead polyvalent dendrimer-based aNP formulation outperformed formulations containing a clinically approved ionizable cationic lipid regarding gene expression in hematopoietic stem and progenitor cells in the bone marrow after intravenous administration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.